A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD)

GlaxoSmithKline1 site in 1 country204 target enrollmentNovember 2004

ConditionsSocial Phobia

Drugsvestipitant/paroxetine

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Social Phobia
Sponsor: GlaxoSmithKline
Enrollment: 204
Locations: 1
Primary Endpoint: Change in score on a Social Anxiety Disorder rating scale following 12 weeks of treatment.
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to assess the efficacy, safety and tolerability of a combination of Vestipitant and Paroxetine in patients with Social Anxiety Disorder (SAD)

Registry

clinicaltrials.gov

Start Date

November 2004

End Date

August 2005

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

GlaxoSmithKline

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Change in score on a Social Anxiety Disorder rating scale following 12 weeks of treatment.

Secondary Outcomes

Change in score on a number of rating scales following 12 weeks of treatment assessing symptomatic, behavioural and functional parameters which together provide a more complete description of the disorder.